Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.
2.

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.

Arch Dermatol. 2005 Jan;141(1):31-8.

PMID:
15655139
4.

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group..

JAMA. 2003 Dec 17;290(23):3073-80. Erratum in: JAMA. 2004 Mar 3;291(9):1070.

PMID:
14679270
5.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

6.

Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.

Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA.

Health Qual Life Outcomes. 2003 Oct 8;1:53.

7.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
8.

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.

Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A; Efalizumab Study Group..

Int J Dermatol. 2006 May;45(5):605-14.

PMID:
16700803
9.

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group..

Br J Dermatol. 2006 Jul;155(1):170-81.

PMID:
16792770
10.

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.

Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x.

PMID:
19903183
11.

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.

Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M.

J Cutan Med Surg. 2005 Dec;9(6):303-12. Review.

PMID:
16699904
12.

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.

Health Qual Life Outcomes. 2006 Sep 27;4:71.

13.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

J Dermatolog Treat. 2007;18(6):341-50.

PMID:
18058494
14.

Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA.

Drug Saf. 2008;31(8):715-26.

PMID:
18636790
15.

Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.

Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI; PEARL investigators..

J Drugs Dermatol. 2012 Aug;11(8):943-9.

PMID:
22859239
16.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
17.

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.

Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG.

Br J Dermatol. 2014 Mar;170(3):705-15. doi: 10.1111/bjd.12636.

18.

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

Br J Dermatol. 2005 May;152(5):954-60.

PMID:
15888152
19.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150.

PMID:
18187944
20.
Items per page

Supplemental Content

Support Center